Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer

• Rumi Fujioka,

  Roles Writing – original draft

  Affiliation Division of Translational Research, Exploratory Oncology and Clinical Trial Center, National Cancer Center, Kashiwa, Japan

  ⨯
• Nobuo Mochizuki,

  Roles Data curation

  Affiliation Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan

  ⨯
• Masafumi Ikeda,

  Roles Supervision

  Affiliation Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center, Hospital East, Kashiwa, Japan

  ⨯
• Akihiro Sato,

  Roles Project administration

  Affiliation Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan

  ⨯
• Shogo Nomura,

  Roles Formal analysis

  Affiliation Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Kashiwa, Japan

  ⨯
• Satoshi Owada,

  Roles Data curation

  Affiliation Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan

  ⨯
• Satoshi Yomoda,

  Roles Investigation

  Affiliation Kanpo Research Institute, Kracie Pharmaceutical Company, Toyama, Japan

  ⨯
• Katsuya Tsuchihara,

  Roles Supervision

  Affiliation Division of Translational Research, Exploratory Oncology and Clinical Trial Center, National Cancer Center, Kashiwa, Japan

  ⨯
• Satoshi Kishino,

  Roles Data curation

  Affiliation Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Tokyo, Japan

  ⨯
• Hiroyasu Esumi

  Roles Conceptualization

  * E-mail: hesumi@rs.tus.ac.jp

  Affiliation Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan

  http://orcid.org/0000-0001-9522-2957

  ⨯